ILSI-Biomed Israel

Aiming for Near-Normal Blood Sugar Did Not Delay Combined Risk of Diabetic Damage for People With Long-standing Diabetes, NIH-Sponsored Trial Finds

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found.  The intensive glucose treatment was compared with standard glucose control. These findings are from the NIH-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.  Although intensive t...

ILSI-BioMed 2010 Has Begun!

This morning the ILSI-BioMed Week 2010 has finally been launched, with 7,000 anticipated participants that will take part in lectures and meetings with the experts and seniors of the bio-pharma and medical equipment industry in Israel and abroad. Following the opening words of the event's organizers, ILSI and Kenes, the president of Israel Shimon Peres came up to the stage and surveyed the future of Israel, which will be based on advanced technologies and serve as an example to the entire...

A French Delegation in the Negev

A French delegation has visited today (Sunday, 13.6.2010) at Ben-Gurion University, as the guest of Bio-Negev, the international center for innovation in the biotechnology industry and life sciences in the Negev. The purpose of the visit is to examine potential collaboration between the visitors and the new initiative in the Negev, BGU being one of the partners in the project. Prof. Rivka Carmi, president of the university, places a great amount of value in the initiative, which can be direct...

Israel’s Life Sciences Export On the Rise

The Coming ILSI–Biomed Israel 2010 Week: The Israel Export and International Cooperation Institute: Life Sciences Export Rose by 14% on the First Quarter of 2010, Summing up to the Total of ca. $1.7 Billion “The first 2010 quarter export of the life sciences industry summed up to ca. $1.7 billion, an increase of about 14 percent compared to the same period last year. This increase is derived from a 15.4 percent increase in the export of medications, which has summed up to ca. $1.3 Billion...

Stem Cells as Seek-and-Destory Missiles against Cancer

As published in New Scientist, stem cells were succesfully modified to act as seek-and-destroy missiles against cancer in mice brains Stem cells are often viewed as the ultimate solution for regenerative medicine, and for a good cause. Given the correct cues, they can regenerate whole parts of the body, and even re-create an entire embryo (although that would require QUITE some understanding of the cues involved in the process). It seems, however, that now a new use has been found for the...

Cardiovascular Therapy in the 2020s

As part of the BioMed Conference, a Cardiovascular Technology Workshop will be held on Monday, June 14, 12:00–18:30 at the Dan Panorama Hotel, Tel Aviv This message is also available online   Cardiovascular Therapy in the 2020s An ILSI-BioMed Workshop Sponsored by As part of the BioMed Conference, a Cardiovascular Technology Workshop will be held on Monday, June 14, 12:00–18:30 at the Dan Panorama Hotel, Tel Aviv.The most acclaimed inte...

Human Beta Cells Grown in a Culture

From BioMed Israel Week 2010: A Novel Therapeutic Method Based on the Ability of Stem Cells to Assist in Treating Juvenile Diabetes Will Replace the Insulin Injection Ramot, Tel Aviv University's technology transfer company, will present for the first time a therapeutic approach based on stem cells capability to assist in the treatment of juvenile diabetes, in the Israel BioMed Week 2010, which will be held on the 14th-16th of June in Tel Aviv. The main novelty of the treatment is a br...

Startup Weekly: ProtAb – Antibodies Against Arthritis

ProtAb is a company dedicated to eveloping an antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn's Disease, and has recently raised $4 million. Name: ProtAb CEO: Shira Yair Sector: Biopharma Medical Field: Autoimmune Diseases Est.: 2005 Stage: Late stage pre-clinical, after series A funding Vision: To develop a novel therapeutics for autoimmune diseases, based on the induction of natural anti-inflammatory mechanisms existing in...

Networking with Five Italian Companies

Five Italian biomedical companies are coming to Israel, and are interested in meeting suitable Israeli business partners It’s not WHAT you know, it’s WHO you know! Relationships are the catalyst for success! Do the above two statements look familiar? They should. They are the axioms of the Networking Theory (name not trademarked, invented on the spot). While networking seems to be the new religion of the business folks, I daresay that it’s been around for quite a bit. Even apes have...

Antioxidants Cause Genetic Abnormalities?

A new research reveals that high doses of antioxidants cause stem cells to develop genetic abnormalities, paving the way for cancer When people look back on the beginning of the 21st century, they might think this was the time of the antioxidants. Antioxidants supplements are being sold everywhere, usually without a doctor prescription, as a way to halt aging, heart diseases and whatever else is promised on the label. But current research, published online in the medical journal Stem Cells, r...